NovaDigm is developing innovative vaccines to protect patients from fungal
and bacterial infections. Our lead product candidates target the fungal
pathogen Candida and the bacterial pathogen Staphylococcus aureus
(S. aureus), including methicillin-resistant S. aureus (MRSA).
These pathogens are increasingly drug-resistant and can lead to recurrent skin
and mucosal infections, as well as life-threatening systemic infections. The
Company’s founding scientists from the Los Angeles Biomedical Research
Institute (LA BioMed) at Harbor-UCLA Medical Center are recognized leaders in
the field of infectious disease and the emerging threat of
“superbugs.” Based in North Dakota with additional research activities at
LA BioMed, NovaDigm has received funding from Domain Associates and
RusnanoMedInvest and collaborates with multiple government agencies.
NovaDigm is conducting a Phase 1b/2a clinical trial to evaluate its lead
vaccine candidate, NDV-3, in patients diagnosed with recurrent vulvovaginal
candidiasis (RVVC), a fungal infection that affects approximately five million
women in the United States. Patients interested in learning more can click here for information on the
clinical trial and here for more
information on RVVC.